Frequency: Every 3-weeks

2 trials

Sponsors

Intas Pharmaceuticals Ltd, Intas Pharmaceuticals Limited

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified siteHealth Condition 1: Z854- Personal history of malignant neoplasm of genital organs

Phase 3

A study to evaluate the efficacy and safety of Test product (Docetaxel of Intas Pharmaceuticals) compared to Reference product (Docetaxel of Sanofi-Aventis) in breast cancer patients.

RecruitingCTRI/2018/06/014390

Intas Pharmaceuticals LimitedHealth Condition 1: C509- Malignant neoplasm of breast of unspecified site

Target: 657Updated: 2026-04-27

Phase 4

A study of Docetaxel Lipid Suspension for Injection in patients with cancer of a gland of the male reproductive system

Active, not recruitingCTRI/2018/02/012212

Intas Pharmaceuticals LtdHealth Condition 1: Z854- Personal history of malignant neoplasm of genital organs

Target: 86Updated: 2021-11-24

Related Papers

Efficacy and safety of nanosomal docetaxel lipid suspension in Indian patients with metastatic castration-resistant prostate cancer (mCRPC): A multicenter, open-label, single-arm phase 4 study.

Journal of Clinical Oncology2025-02-10